{"id":2669,"date":"2018-06-18T15:59:11","date_gmt":"2018-06-18T10:29:11","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2669"},"modified":"2024-09-18T15:07:41","modified_gmt":"2024-09-18T09:37:41","slug":"nf-%ce%bab-inhibitors-promising-future","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/nf-%ce%bab-inhibitors-promising-future","title":{"rendered":"NF-\u03baB Inhibitors- A Promising Future"},"content":{"rendered":"<p style=\"text-align: justify;\">NF-\u03baB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory response and cellular responses. NF-\u03baB is also involved in producing the synergistic immune responses.<\/p>\n<p style=\"text-align: justify;\">NF-\u03baB inhibitors has a great scope in the wide areas. NF-\u03baB has a robust role in cellular stress, immune responses, inflammation and its mediators playing a significant role in various indications such as cancers, autoimmune diseases, addictions, inflammations, etc. Looking at the functions and targets of NF-\u03baB, it is under a keen inspection for developing the various interventions. NF-\u03baB inhibitors holds a promising place for the further developments.<\/p>\n<ul style=\"text-align: justify;\">\n<li>NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity. Blocking NF-\u03baB can cause tumor cells to stop proliferating, to die, or to become more sensitive to the action of anti-tumor agents. Thus, NF-\u03baB is the subject of much active research among pharmaceutical companies as a target for anti-cancer therapy<\/li>\n<li>In cancer, mechanisms that regulate gene expression in response to inflammatory stimuli are altered to the point that a cell ceases to link its survival with the mechanisms that coordinate its phenotype and its function with the rest of the tissue<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">\n<p style=\"text-align: justify;\">Currently, various companies are working in this area contributing towards a strong pipeline of about 12+ active products. Companies like AnGes, MedDay Pharmaceuticals and Reata Pharmaceuticals, are the key players amongst the developers of the late-stage emerging therapies followed by Constellation, Catabasis, Neurmedix and others. AnGes and Catabasis are leading in the development of maximum number of NF-kB Inhibitors.<\/p>\n<p style=\"text-align: justify;\">Some of the key emerging therapies are as follows:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Reata\u2019s Bardoxolone Methyl is under development by Reata Pharmaceuticals in late clinical stage has received Sakigake priority review designation Japan for the treatment of diabetic kidney disease (DKD). Also, the drug has been awarded by Orphan Drug Designation by USFDA for various indications such as Pulmonary Arterial Hypertension, Pancreatic Cancer, and others. These designations points towards the potential chance of the drug to emerge as successful therapy<\/li>\n<li>AnGes\u2019s AMG0101 has completed the phase III trials (ointment) in Japan for Atopic&nbsp;Dermatitis. The same drug is under phase I trial for Low&nbsp;Back&nbsp;Pain&nbsp;due&nbsp;to&nbsp;Disc&nbsp;Degeneration in United States<\/li>\n<li>MedDay Pharmaceuticals\u2019 MD-1003 is under Phase III stage of development as the most promising emerging therapy for the future<\/li>\n<li>Catabasis\u2019s Edasalonexent (CAT-1004) is being evaluated for phase II clinical studies by Catabasis Pharmaceuticals. The potential candidate has been awarded with orphan drug, fast track and rare pediatric disease designations for the treatment of Duchenne muscular dystrophy (DMD) The U.S. Food and Drug Administration (FDA) and orphan medicinal product designation by the European Commission (EC). This signifies the promising future CAT-1004<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">The pipeline of NF-kB inhibitors has to emerge with the advancement and rapid development in the research and knowledge. Most of the drug candidates in the NF-kB inhibitors therapeutics pipeline are being developed as small molecule using synthetic source. Currently, the companies are focusing on developing target specific and personalized medicine for the better treatment with reduced adverse events. Thus, NF-kB inhibitors therapeutics pipeline is likely to grow significantly, in the future, for the treatment of various diseases including cancer and chronic inflammation.<\/p>\n<p style=\"text-align: justify;\"><strong><em>Rakhee Varshneya<\/em><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;&nbsp; Associate Analyst <\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>NF-\u03baB (Nuclear Factor kappa-light-chain-enhancer of activated B cells) is a protein transcription factor that can orchestrate complex biological processes such as cell survival, cytokine production, inflammatory response and cellular responses. NF-\u03baB is also involved in producing the synergistic immune responses. NF-\u03baB inhibitors has a great scope in the wide areas. NF-\u03baB has a robust role [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1648,1649,204,1611,1261,706],"industry":[17225],"therapeutic_areas":[17242,17228,17234],"class_list":["post-2669","post","type-post","status-publish","format-standard","hentry","category-articles","tag-angess-amg0101","tag-catabasiss-edasalonexent","tag-delveinsight","tag-nf-b","tag-pharma-consulting","tag-pharmaceutical-industry","industry-pharmaceutical","therapeutic_areas-cardiovascular-diseases","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>NF-\u03baB Inhibitors- A Promising Future - DelveInsight Business Research<\/title>\n<meta name=\"description\" content=\"NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/nf-\u03bab-inhibitors-promising-future\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"NF-\u03baB Inhibitors- A Promising Future - DelveInsight Business Research\" \/>\n<meta property=\"og:description\" content=\"NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/nf-\u03bab-inhibitors-promising-future\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-06-18T10:29:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-18T09:37:41+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"NF-\u03baB Inhibitors- A Promising Future - DelveInsight Business Research","description":"NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/nf-\u03bab-inhibitors-promising-future","og_locale":"en_US","og_type":"article","og_title":"NF-\u03baB Inhibitors- A Promising Future - DelveInsight Business Research","og_description":"NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity.","og_url":"https:\/\/www.delveinsight.com\/blog\/nf-\u03bab-inhibitors-promising-future","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-06-18T10:29:11+00:00","article_modified_time":"2024-09-18T09:37:41+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/nf-%ce%bab-inhibitors-promising-future","url":"https:\/\/www.delveinsight.com\/blog\/nf-%ce%bab-inhibitors-promising-future","name":"NF-\u03baB Inhibitors- A Promising Future - DelveInsight Business Research","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-06-18T10:29:11+00:00","dateModified":"2024-09-18T09:37:41+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"NF-\u03baB is active in tumor cells either due to mutations in genes encoding the NF-\u03baB transcription factors themselves or in genes that control NF-\u03baB activity.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/nf-%ce%bab-inhibitors-promising-future"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">AnGes\u2019s AMG0101<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Catabasis\u2019s Edasalonexent<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">NF-\u03baB<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AnGes\u2019s AMG0101<\/span>","<span class=\"advgb-post-tax-term\">Catabasis\u2019s Edasalonexent<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">NF-\u03baB<\/span>","<span class=\"advgb-post-tax-term\">pharma consulting<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Jun 18, 2018","modified":"Updated on Sep 18, 2024"},"absolute_dates_time":{"created":"Posted on Jun 18, 2018 3:59 pm","modified":"Updated on Sep 18, 2024 3:07 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2669","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2669"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2669\/revisions"}],"predecessor-version":[{"id":29619,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2669\/revisions\/29619"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2669"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2669"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2669"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2669"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2669"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}